Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018 | Addiction Medicine | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018

Educational Objective
To understand trends in the use of medications for opioid use disorder.
1 Credit CME
Key Points

Question  Did treatment of opioid use disorder (OUD) among Medicaid enrollees change from 2014 to 2018?

Findings  In this exploratory serial cross-sectional study using data from 1 024 301 Medicaid enrollees in 11 states, the prevalence of medication treatment for OUD increased from 47.8% (138 918 of 290 638 enrollees with OUD) in 2014 to 57.1% (301 499 of 527 983) in 2018. There was substantial variation across and within states in any use and continuity (for 180 days) of medications for OUD by age, race/ethnicity, eligibility group, behavioral health comorbidity, and rural vs urban residence.

Meaning  From 2014 through 2018, use of medications for opioid use disorder increased among Medicaid enrollees in 11 US states, but the pattern in the other states is not known.

Abstract

Importance  There is limited information about trends in the treatment of opioid use disorder (OUD) among Medicaid enrollees.

Objective  To examine the use of medications for OUD and potential indicators of quality of care in multiple states.

Design, Setting, and Participants  Exploratory serial cross-sectional study of 1 024 301 Medicaid enrollees in 11 states aged 12 through 64 years (not eligible for Medicare) with International Classification of Diseases, Ninth Revision (ICD-9 or ICD-10) codes for OUD from 2014 through 2018. Each state used generalized estimating equations to estimate associations between enrollee characteristics and outcome measure prevalence, subsequently pooled to generate global estimates using random effects meta-analyses.

Exposures  Calendar year, demographic characteristics, eligibility groups, and comorbidities.

Main Outcomes and Measures  Use of medications for OUD (buprenorphine, methadone, or naltrexone); potential indicators of good quality (OUD medication continuity for 180 days, behavioral health counseling, urine drug tests); potential indicators of poor quality (prescribing of opioid analgesics and benzodiazepines).

Results  In 2018, 41.7% of Medicaid enrollees with OUD were aged 21 through 34 years, 51.2% were female, 76.1% were non-Hispanic White, 50.7% were eligible through Medicaid expansion, and 50.6% had other substance use disorders. Prevalence of OUD increased in these 11 states from 3.3% (290 628 of 8 737 082) in 2014 to 5.0% (527 983 of 10 585 790) in 2018. The pooled prevalence of enrollees with OUD receiving medication treatment increased from 47.8% in 2014 (range across states, 35.3% to 74.5%) to 57.1% in 2018 (range, 45.7% to 71.7%). The overall prevalence of enrollees receiving 180 days of continuous medications for OUD did not significantly change from the 2014-2015 to 2017-2018 periods (−0.01 prevalence difference, 95% CI, −0.03 to 0.02) with state variability in trend (90% prediction interval, −0.08 to 0.06). Non-Hispanic Black enrollees had lower OUD medication use than White enrollees (prevalence ratio [PR], 0.72; 95% CI, 0.64 to 0.81; P < .001; 90% prediction interval, 0.52 to 1.00). Pregnant women had higher use of OUD medications (PR, 1.18; 95% CI, 1.11-1.25; P < .001; 90% prediction interval, 1.01-1.38) and medication continuity (PR, 1.14; 95% CI, 1.10-1.17, P < .001; 90% prediction interval, 1.06-1.22) than did other eligibility groups.

Conclusions and Relevance  Among US Medicaid enrollees in 11 states, the prevalence of medication use for treatment of opioid use disorder increased from 2014 through 2018. The pattern in other states requires further research.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Julie M. Donohue, PhD, Health Policy and Management, University of Pittsburgh Graduate School of Public Health, 130 DeSoto St, A635, Pittsburgh, PA 15261 (jdonohue@pitt.edu).

Accepted for Publication: April 22, 2021.

The MODRN Group Writers: Julie M. Donohue, PhD; Marian P. Jarlenski, PhD; Joo Yeon Kim, MS; Lu Tang, PhD; Katherine Ahrens, PhD; Lindsay Allen, PhD; Anna Austin, PhD; Andrew J. Barnes, PhD; Marguerite Burns, PhD; Chung-Chou H. Chang, PhD; Sarah Clark, MPH; Evan Cole, PhD; Dushka Crane, PhD; Peter Cunningham, PhD; David Idala, MA; Stefanie Junker, MPH; Paul Lanier, PhD; Rachel Mauk, PhD; Mary Joan McDuffie, MA; Shamis Mohamoud, MA; Nathan Pauly, PhD; Logan Sheets, BA; Jeffery Talbert, PhD; Kara Zivin, PhD, MS, MA; Adam J. Gordon, MD, MPH; Susan Kennedy, MPP, MSW.

Affiliations of The MODRN Group Writers: Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Donohue, Jarlenski, Kim, Cole, Junker); Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Tang); Public Health Program, Muskie School of Public Service, University of Southern Maine, Portland (Ahrens); Health Policy, Management, and Leadership Department, School of Public Health, West Virginia University, Morgantown (Allen); Department of Maternal and Child Health, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (Austin); Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond (Barnes, Cunningham); Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison (Burns); Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (Chang); Department of Pediatrics, University of Michigan Medical School, Ann Arbor (Clark); Ohio Colleges of Medicine Government Resource Center, The Ohio State University, Columbus (Crane, Mauk); The Hilltop Institute, University of Maryland Baltimore County, Baltimore (Idala, Mohamoud); School of Social Work, University of North Carolina at Chapel Hill (Lanier); Center for Community Research & Service, Biden School of Public Policy and Administration, University of Delaware, Newark (McDuffie); Health Sciences Center, School of Public Health, Health Affairs Department, School of Public Health, West Virginia University, Morgantown (Pauly); AcademyHealth, Washington, DC (Sheets, Kennedy); Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington (Talbert); Department of Psychiatry, University of Michigan Medical School, Ann Arbor (Zivin); Department of Medicine and Department of Psychiatry, University of Utah School of Medicine, Salt Lake City (Gordon); Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City (Gordon).

Author Contributions: Dr Donohue had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Donohue, Tang, Allen, Austin, Burns, Crane, Cunningham, Junker, Lanier, Mohamoud, Sheets, Talbert, Gordon, Kennedy.

Acquisition, analysis, or interpretation of data: Donohue, Jarlenski, Kim, Tang, Ahrens, Allen, Austin, Barnes, Burns, Chang, Clark, Cole, Crane, Cunningham, Idala, Lanier, Mauk, McDuffie, Mohamoud, Pauly, Talbert, Zivin, Gordon.

Drafting of the manuscript: Donohue, Tang, Gordon, Kennedy.

Critical revision of the manuscript for important intellectual content: Donohue, Jarlenski, Kim, Tang, Ahrens, Allen, Austin, Barnes, Burns, Chang, Clark, Cole, Crane, Cunningham, Idala, Junker, Lanier, Mauk, McDuffie, Mohamoud, Pauly, Sheets, Talbert, Zivin, Gordon.

Statistical analysis: Kim, Tang, Ahrens, Austin, Barnes, Cunningham, Idala, Lanier, McDuffie.

Obtained funding: Donohue, Crane.

Administrative, technical, or material support: Donohue, Jarlenski, Kim, Barnes, Burns, Cole, Crane, Cunningham, Junker, Lanier, Mohamoud, Pauly, Sheets, Talbert, Zivin, Gordon, Kennedy.

Supervision: Donohue, Chang, Crane, Zivin.

Conflict of Interest Disclosures: Dr Ahrens reported receiving support from the Maine Department of Health cooperative agreement. Dr Chang reported receiving grants from National Institutes of Health (NIH). Dr Cunningham reported receiving support from the Virginia Department of Medical Assistance contract to evaluate Addiction and Recovery Treatment Services program. Dr Mauk reported receiving grants from the NIH and support from the Ohio Department of Medicaid. Ms McDuffie reported receiving grants from the Delaware Division of Medicaid and Medical Assistance. Dr Gordon reported receiving institutional support from grants CIN 13-414 from the Department of Veterans Affairs' Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center of Innovation, and 1UG1DA049444-01 from the National Institute on Drug Abuse; serving on the board of directors (not compensated) for the American Society of Addiction Medicine (ASAM), the Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA), and the International Society of Addiction Journal Editors (ISAJE); and receiving royalties from the medical online reference, UpToDate. No other disclosures were reported.

Funding/Support: This study was supported by grant R01DA048029 from the National Institute on Drug Abuse (Drs Donohue, Allen, Cole, Crane, Cunningham, Mauk, Talbert, and Zivin and Ms Maohamoud and Mr Sheets).

Role of the Funder/Sponsor: The National Institute on Drug Abuse had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Collaborator Information: The MODRN Collaborators are listed in Supplement 2.

References
1.
Larochelle  MR , Bernson  D , Land  T ,  et al.  Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.   Ann Intern Med. 2018;169(3):137-145. doi:10.7326/M17-3107PubMedGoogle ScholarCrossref
2.
Kaiser Family Foundation. Medicaid’s role in addressing the opioid epidemic. Published 2018. Accessed May 14, 2018. https://www.kff.org/infographic/medicaids-role-in-addressing-opioid-epidemic/
3.
McCarty  D , Gu  Y , McIlveen  JW , Lind  BK .  Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis.   Addict Sci Clin Pract. 2019;14(1):31. doi:10.1186/s13722-019-0160-6PubMedGoogle ScholarCrossref
4.
Report to Congress: utilization management of medication-assisted treatment in Medicaid. Medicaid and CHIP Payment and Access Commission. October 2019. Accessed June 13, 2021. https://www.macpac.gov/publication/report-to-congress-utilization-management-of-medication-assisted-treatment-in-medicaid/
5.
Barnes  AJ , Cunningham  PJ , Saxe-Walker  L ,  et al.  Hospital use declines after implementation of Virginia Medicaid’s addiction and recovery treatment services.   Health Aff (Millwood). 2020;39(2):238-246. doi:10.1377/hlthaff.2019.00525PubMedGoogle ScholarCrossref
6.
Shen  K , Barrette  E , Dafny  LS .  Treatment of opioid use disorder among commercially insured US adults, 2008-17.   Health Aff (Millwood). 2020;39(6):993-1001. doi:10.1377/hlthaff.2019.01041PubMedGoogle ScholarCrossref
7.
Clemans-Cope  L , Lynch  V , Winiski  E , Epstein  M . State variation in Medicaid prescriptions for opioid use disorder from 2011 to 2018. Urban Institute. Published August 2019. Accessed June 13, 2021. https://www.urban.org/research/publication/state-variation-medicaid-prescriptions-opioid-use-disorder-2011-2018
8.
Roberts  AW , Saloner  B , Dusetzina  SB .  Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015.   Psychiatr Serv. 2018;69(7):832-835. doi:10.1176/appi.ps.201700315PubMedGoogle ScholarCrossref
9.
Academy Health. Medicaid Outcomes Distributed Research Network (MODRN). Accessed June 20, 2020.https://www.academyhealth.org/MODRN
10.
Centers for Disease Control and Prevention. 2018 drug overdose death rates. Last reviewed March 22, 2021. Accessed June 20, 2020. https://www.cdc.gov/drugoverdose/data/statedeaths/drug-overdose-death-2018.html
11.
Toh  S , Platt  R , Steiner  JF , Brown  JS .  Comparative-effectiveness research in distributed health data networks.   Clin Pharmacol Ther. 2011;90(6):883-887. doi:10.1038/clpt.2011.236PubMedGoogle ScholarCrossref
12.
National Quality Forum. Continuity of pharmacotherapy for opioid use disorder (OUD)–national quality strategy domain: effective clinical care–meaningful measure area: prevention and treatment of opioid and substance use disorders. Published 2019. Accessed July 21, 2020. https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_468_MIPSCQM.pdf
13.
National Quality Forum. Opioids and opioid use disorder: quality measurement priorities. Published February 2020. Accessed July 21, 2020. https://www.qualityforum.org/Publications/2020/02/Opioids_and_Opioid_Use_Disorder__Quality_Measurement_Priorities.aspx
14.
Martin  SA , Chiodo  LM , Bosse  JD , Wilson  A .  The next stage of buprenorphine care for opioid use disorder.   Ann Intern Med. 2018;169(9):628-635. doi:10.7326/M18-1652PubMedGoogle ScholarCrossref
15.
Watkins  KE , Paddock  SM , Hudson  TJ ,  et al.  Association between process measures and mortality in individuals with opioid use disorders.   Drug Alcohol Depend. 2017;177:307-314. doi:10.1016/j.drugalcdep.2017.03.033PubMedGoogle ScholarCrossref
16.
Gordon  AJ , Lo-Ciganic  WH , Cochran  G ,  et al.  Patterns and quality of buprenorphine opioid agonist treatment in a large Medicaid program.   J Addict Med. 2015;9(6):470-477. doi:10.1097/ADM.0000000000000164PubMedGoogle ScholarCrossref
17.
Park  TW , Larochelle  MR , Saitz  R , Wang  N , Bernson  D , Walley  AY .  Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.   Addiction. 2020;115(5):924-932. doi:10.1111/add.14886PubMedGoogle ScholarCrossref
18.
Neighbors  CJ , Choi  S , Healy  S , Yerneni  R , Sun  T , Shapoval  L .  Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.   Subst Abuse Treat Prev Policy. 2019;14(1):28. doi:10.1186/s13011-019-0215-4PubMedGoogle ScholarCrossref
19.
Samples  H , Williams  AR , Olfson  M , Crystal  S .  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.   J Subst Abuse Treat. 2018;95:9-17. doi:10.1016/j.jsat.2018.09.001PubMedGoogle ScholarCrossref
20.
Economic Research Service, US Department of Agriculture. Rural urban commuting area codes. Published 2019. Accessed August 5, 2020. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/
21.
Liang  K , Zeger  S .  Longitudinal data analysis using generalized linear models.   Biometrika. 1986;73:13-22. doi:10.1093/biomet/73.1.13Google ScholarCrossref
22.
Toh  S , Gagne  JJ , Rassen  JA , Fireman  BH , Kulldorff  M , Brown  JS .  Confounding adjustment in comparative effectiveness research conducted within distributed research networks.   Med Care. 2013;51(8)(suppl 3):S4-S10. doi:10.1097/MLR.0b013e31829b1bb1PubMedGoogle Scholar
23.
Toh  S , Shetterly  S , Powers  JD , Arterburn  D .  Privacy-preserving analytic methods for multisite comparative effectiveness and patient-centered outcomes research.   Med Care. 2014;52(7):664-668. doi:10.1097/MLR.0000000000000147PubMedGoogle ScholarCrossref
24.
Deeks  JJ , Higgins  JP , Altman  DG ; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Green  S , ed.  Cochrane Handbook for Systematic Reviews of Interventions. Wiley Blackwell. 2019:241-284. doi:10.1002/9781119536604.ch10
25.
IntHout  J , Ioannidis  JP , Borm  GF .  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method.   BMC Med Res Methodol. 2014;14(1):25. doi:10.1186/1471-2288-14-25PubMedGoogle ScholarCrossref
26.
Borenstein  M , Hedges  LV , Higgins  JPT , Rothstein  HR .  A basic introduction to fixed-effect and random-effects models for meta-analysis.   Res Synth Methods. 2010;1(2):97-111. doi:10.1002/jrsm.12PubMedGoogle ScholarCrossref
27.
Carrell  DS , Albertson-Junkans  L , Ramaprasan  A ,  et al.  Measuring problem prescription opioid use among patients receiving long-term opioid analgesic treatment: development and evaluation of an algorithm for use in EHR and claims data.   J Drug Assess. 2020;9(1):97-105. doi:10.1080/21556660.2020.1750419PubMedGoogle ScholarCrossref
28.
Howell  BA , Abel  EA , Park  D , Edmond  SN , Leisch  LJ , Becker  WC .  Validity of incident opioid use disorder (OUD)diagnoses in administrative data: a chart verification study.   J Gen Intern Med. 2021;36(5):1264-1270. doi:10.1007/s11606-020-06339-3 PubMedGoogle ScholarCrossref
29.
Bipartisan Policy Center. Tracking federal funding to combat the opioid crisis. Published 2019. Accessed June 13, 2021. https://bipartisanpolicy.org/wp-content/uploads/2019/03/Tracking-Federal-Funding-to-Combat-the-Opioid-Crisis.pdf
30.
Cunningham  P , Woodcock  C , Clark  M ,  et al. Expanding access to addiction treatment services through Section 1115 waivers for substance use disorders: experiences from Virginia and Maryland. AcademyHealth. Published April 2020. Accessed June 13, 2021. https://www.academyhealth.org/sites/default/files/expandingaccesstoaddictiontreatmentthrough1115waivers_april2020.pdf
31.
Azar  A  II . US Department of Health and Human Services. Report to Congress, T-MSIS substance use disorder (SUD) data book, treatment of SUD in Medicaid, 2017. Published October 24, 2019. Accessed August 25, 2020. https://www.medicaid.gov/medicaid/data-and-systems/downloads/macbis/sud-data-book.pdf
32.
Cher  BAY , Morden  NE , Meara  E .  Medicaid expansion and prescription trends: opioids, addiction therapies, and other drugs.   Med Care. 2019;57(3):208-212. doi:10.1097/MLR.0000000000001054 PubMedGoogle ScholarCrossref
33.
Wen  H , Hockenberry  JM , Borders  TF , Druss  BG .  Impact of Medicaid expansion on Medicaid-covered utilization of buprenorphine for opioid use disorder treatment.   Med Care. 2017;55(4):336-341. doi:10.1097/MLR.0000000000000703 PubMedGoogle ScholarCrossref
34.
American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder 2020 focused update. Adopted by the board of directors December 18, 2019. Accessed June 13, 2021. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf
35.
Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for the management of substance. Published 2015. Accessed June 13, 2021. https://www.healthquality.va.gov/guidelines/mh/sud/
36.
Substance Abuse and Mental Health Services Administration.  Medications for Opioid Use Disorder: Treatment Improvement Protocol (TIP 63). Substance Abuse and Mental Health Services Administration; 2020.
37.
Cole  ES , DiDomenico  E , Cochran  G ,  et al.  The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder.   J Gen Intern Med. 2019;34(6):936-943. doi:10.1007/s11606-019-04943-6 PubMedGoogle ScholarCrossref
38.
Hansen  H , Siegel  C , Wanderling  J , DiRocco  D .  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.   Drug Alcohol Depend. 2016;164:14-21. doi:10.1016/j.drugalcdep.2016.03.028PubMedGoogle ScholarCrossref
39.
Andrilla  CHA , Moore  TE , Patterson  DG , Larson  EH .  Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update.   J Rural Health. 2019;35(1):108-112. doi:10.1111/jrh.12307PubMedGoogle ScholarCrossref
40.
Stein  BD , Pacula  RL , Gordon  AJ ,  et al.  Where is buprenorphine dispensed to treat opioid use disorders? the role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties.   Milbank Q. 2015;93(3):561-583. doi:10.1111/1468-0009.12137PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close